Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last1,821 to 1,840 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Clopidogrel vs Placebo: Myocardial Infarction | 10 of 2,432 7 of 2,449 | 0.1 points -0.2 to 0.5 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Minor Hemorrhage | 40 of 2,432 13 of 2,449 | 1.1 points 0.5 to 1.7 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Death From Ischemic Vascular Causes | 6 of 2,432 4 of 2,449 | 0.1 points -0.2 to 0.4 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Hemorrhagic Stroke | 5 of 2,432 3 of 2,449 | 0.1 points -0.2 to 0.4 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Other Symptomatic Intracranial Hemorrhage | 2 of 2,432 0 of 2,449 | 0.1 points -0.1 to 0.3 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Death From Any Cause | 18 of 2,432 12 of 2,449 | 0.3 points -0.2 to 0.7 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Ischemic Stroke | 112 of 2,432 155 of 2,449 | -1.7 points -3.0 to -0.4 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Ischemic or Hemorrhagic Stroke | 116 of 2,432 156 of 2,449 | -1.6 points -2.9 to -0.3 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Major Hemorrhage | 23 of 2,432 10 of 2,449 | 0.5 points 0.1 to 1.0 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: deaths from any cause | 18 of 2,432 12 of 2,449 | 0.3 points -0.2 to 0.7 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: Composite of Ischemic Stroke, Myocardial Infarction, Death From Ischemic Vascular Causes, or Major Hemorrhage | 141 of 2,432 167 of 2,449 | -1.0 points -2.4 to 0.3 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Clopidogrel vs Placebo: serious adverse events | 382 of 2,432 382 of 2,449 | 0.1 points -1.9 to 2.1 | 4,881 | NCT00991029 Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial |
| Treatment - Participation in Nurse Family Partnership Nurse-Family Partnership vs Control: Number of Participants With a Postpartum Visit | 2,079 of 3,261 1,038 of 1,616 | -0.5 points -3.3 to 2.4 | 4,877 | NCT03360539 Nurse-Family Partnership Impact Evaluation in South Carolina |
| Cervarix/Engerix-B Pooled Group vs Engerix-B Group: Number of Female Subjects With Total Vaccine Effectiveness Against Oropharyngeal Infection With HPV-16/18 Types | 9 of 3,192 27 of 1,679 | -1.3 points -2.1 to -0.8 | 4,871 | NCT00534638 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents |
| Early Intervention vs Late Implementation: Patients Indicated for ACE/ARB and Statin Who Had an Active Prescription for Both | 1,279 of 2,053 1,318 of 2,803 | 15.3 points 12.5 to 18.1 | 4,856 | NCT02299791 Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics |
| Counselor vs Provider: Test Offer Rate | 1,959 of 2,446 861 of 2,409 | 44.3 points 41.8 to 46.8 | 4,855 | NCT00502944 Two Approaches to Routine HIV Testing in a Hospital Emergency Department |
| Counselor vs Provider: Overall Rapid HIV Testing Rate | 1,382 of 2,446 643 of 2,409 | 29.8 points 27.1 to 32.4 | 4,855 | NCT00502944 Two Approaches to Routine HIV Testing in a Hospital Emergency Department |
| Arm A: Continuous Letrozole vs Arm B: Intermittent Letrozole: deaths from any cause | 170 of 2,426 146 of 2,425 | 1.0 points -0.4 to 2.4 | 4,851 | NCT00553410 Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer |
| Intervention vs Control: 30-day COPD Specific, Acute Care Utilization to Any Hospital Within the System | 179 of 2,353 240 of 2,479 | -2.1 points -3.7 to -0.5 | 4,832 | NCT03207776 An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD |
| Intervention vs Control: Quality, Comfort, and Care (QCC) Defined Readmission Rate | 286 of 2,353 321 of 2,479 | -0.8 points -2.7 to 1.1 | 4,832 | NCT03207776 An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=92
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT00991029-7aa4d7cb",
"title": "Clopidogrel vs Placebo: Myocardial Infarction",
"summary": "10 of 2432 against 7 of 2449; risk difference 0.1 points, 95% interval -0.2 to 0.5; NCT00991029, Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial",
"record": "/library/comparisons/NCT00991029-7aa4d7cb",
"nct_id": "NCT00991029",
"kind": "outcome",
"participants": 4881,
"risk_difference": {
"value": 0.001253532591175775,
"lower": -0.0023108328301578804,
"upper": 0.004996485339499869
},
"group_1": "10 of 2,432",
"group_2": "7 of 2,449",
"difference": "0.1 points",
"interval": "-0.2 to 0.5",
"trial_title": "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial"
},
{
"id": "NCT00991029-8a641897",
"title": "Clopidogrel vs Placebo: Minor Hemorrhage",
"summary": "40 of 2432 against 13 of 2449; risk difference 1.1 points, 95% interval 0.5 to 1.7; NCT00991029, Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial",
"record": "/library/comparisons/NCT00991029-8a641897",
"nct_id": "NCT00991029",
"kind": "outcome",
"participants": 4881,
"risk_difference": {
"value": 0.011139079323461778,
"lower": 0.005397258683544695,
"upper": 0.017409714417275447
},
"group_1": "40 of 2,432",
"group_2": "13 of 2,449",
"difference": "1.1 points",
"interval": "0.5 to 1.7",
"trial_title": "Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=93",
"request_id": "kIYt_n0pK1aKn26b"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant